What the US Big-3 tells us about where India's distribution goes
Three companies move more than 90% of US drug distribution today. Fifty years ago, that market looked a lot like India does now. The forces that consolidated it are the same forces switching on here.
If you want to know where a fragmented distribution market ends up, you don't need a forecast. You need a map of somewhere that already made the journey. For pharmaceutical distribution, that map is the United States.
Three companies, ninety percent
Today, American drug distribution is one of the most concentrated essential industries in the world. McKesson, Cencora, and Cardinal Health together move more than 90% of the market. Everything else — every regional player, every specialty distributor — fits into the sliver that's left.
The gap is the opportunity. The US shows where density wins. India still runs the overwhelming majority of its volume through tens of thousands of local distributors. Illustrative; not to scale.
It didn't start that way
Rewind a couple of generations and the American picture was almost unrecognisable: hundreds of regional drug wholesalers, each strong in its own geography, none with a national footprint. There was no centre of gravity. Sound familiar?
What changed wasn't a single event. It was the slow, compounding logic of the business itself. Distribution rewards three things — density (more drops per route), working capital (the ability to fund inventory and credit at scale), and reach (the breadth to serve any customer, anywhere). Each of those gets cheaper per unit as you get bigger. So the big got bigger, and the curve bent toward consolidation until three names were left standing.
The same forces are switching on in India
India sits early on that same curve. The top national players handle a small share of the market; the overwhelming majority of volume still flows through a long tail of local distributors — the roughly 80,000 distributors and stockists that connect about 3,000 manufacturers to some 9 lakh pharmacies.
The forces, though, are identical. GST and digitisation are making the trade legible. Working capital is getting more expensive for the undercapitalised. Manufacturers want fewer, more reliable counterparties. Every one of these pushes in the same direction the US already travelled.
What the precedent does not tell us
Precedent is a compass, not a script. Two things about India will not rhyme with America.
First, retail won't consolidate the same way. The American pharmacy chain is a different animal; in India the last mile stays local, because trust and proximity at the counter don't scale into a few brands. We don't expect that to change, and our thesis doesn't need it to.
Second, the winner here will be software-native. The US Big-3 consolidated largely before modern software; they bolted technology on afterwards. In India, the consolidation and the operating system can be built together from day one — which is a structural advantage the American incumbents never had.
The takeaway
The US isn't a promise that India will look identical. It's proof that a fragmented distribution market, left to its own economics, resolves toward scale — and that the resolving is worth an enormous amount to whoever leads it. India is early on that curve. The forces are on. The question, as ever, is who does the consolidating, and whether they own the rails while they do it.
The Founder's Office is our monthly read on Indian pharma — the macro forces, the structural shifts, and what they mean for everyone building in this market. We teach what we see; we don't talk anyone down.